A further and highly significant improvement in the pharmacology of mAbs was achieved with the production of humanized anti-TNF-α mAbs such as ADA and GOL, bringing the great advantage of reduced immunogenicity while still maintaining certain limitations [ 17 , 18 ].
← all excerpts
Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region.
1
—
—